Skip to main content
Access Bio, Inc. logo

Access Bio, Inc. — Investor Relations & Filings

Ticker · 950130 ISIN · KR8840090003 LEI · 335800Q5TV77F4L9Q648 KO Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2020-12-03 Capital/Financing Update
Country IN India
Listing KO 950130

About Access Bio, Inc.

https://accessbio.net/

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) by Access Bio. It details the contract value, the counterparty (Intrivo Diagnostics), the product (COVID-19 antigen test kits), and the contract period. Since this is a specific regulatory announcement of a material business contract that does not fit into the other specialized categories like M&A or financial reports, it is classified as a Regulatory Filing (RNS).
2020-12-03 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory disclosure regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) for COVID-19 antigen test kits. It details the contract amount, the counterparty (Intrivo Diagnostics), the contract period, and the impact on revenue. Since this is a specific announcement of a commercial contract and does not fit into the other categories like M&A or financial reports, it is classified as a general regulatory filing.
2020-11-20 Korean
신규시설투자등
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from Access Bio regarding a 'New Facility Investment' (신규시설투자). It details the investment amount, purpose (expanding production capacity for COVID-19 diagnostic kits), and board approval details. Since this is a specific corporate announcement regarding capital expenditure and facility investment that does not fit into the other specific categories like M&A or share issues, it is classified as a general regulatory filing.
2020-11-20 Korean
증권발행결과(자율공시)(제4회차 CB)
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a convertible bond, or CB). It details the type of security, the issuance amount, the payment date, and the method of issuance. This falls under the category of capital and financing updates, specifically related to the issuance of new financial instruments.
2020-11-18 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Major Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정). It explicitly lists the 'Correction Subject' (정정대상) as the 'Major Report' filed on November 16, 2020, and details the specific changes made to the conversion period dates. Since this is a regulatory filing detailing a change in capital structure (issuance of convertible bonds) and is not a standalone annual report or a simple announcement of a report, it falls under the category of capital/financing updates.
2020-11-18 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission in South Korea. It details the issuance of convertible bonds (전환사채권 발행결정) by Access Bio, including terms such as interest rates, conversion prices, and the identity of the investor (Ginkgo Bioworks, Inc.). This type of filing is a standard regulatory disclosure regarding capital structure changes and financing activities, which falls under the 'Capital/Financing Update' category.
2020-11-16 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.